

Datasheet for ABIN5298081

## Human CMM CRISPR gRNA + Cas9 in Lenti Particles

### Overview

Quantity:	300 µL
Gene:	Cutaneous Malignant Melanoma/dysplastic Nevus (CMM)
Species:	Human
Insert:	gRNA + Cas9
Vector:	Lentiviral Vector
Application:	Genome Editing with Engineered Nucleases (GEEN), Protein Expression (PExp)

### Product Details

Purpose:	Individual gRNA against CMM in Lentiviral Particles with a Titer of >1x10e7 IU/mL. (sgRNA and Cas9 in a single vector)
Vector Backbone:	pLenti-U6-sgRNA-SFFV-Cas9-2A-Puro
Promoter:	U6 Promoter, SFFV Promoter
Selectable Marker:	Puromycin
Bacterial Resistance:	Ampicillin
Expression Type:	Stable, Transient
Sequence:	Sequence available upon placing order
Specificity:	GRNAs are designed for use with Cas9 Nuclease only. Cas9 Nuclease is under the control of the SFFV promoter which should work for a vast majority of cells, except ES cells or iPS cells.
Sequencing Primer:	U6 Forward Primer: 5'--TACGTCCAAGGTCGGGCAGGAAGA--3'
Components:	Lentiviral particles with an individual gRNA (300 µL) for a specific sequence of CMM

Order at [www.genomics-online.com](http://www.genomics-online.com)

USA & Canada: +1 877 302 8632 | [support@antibodies-online.com](mailto:support@antibodies-online.com)

## Target Details

---

Gene: Cutaneous Malignant Melanoma/dysplastic Nevus (CMM)

---

Alternative Name: CMM

## Application Details

---

Application Notes: Recommended for quality control: Restriction Enzyme Digest and Sequencing

---

Restrictions: For Research Use only

## Handling

---

Format: Viral Particles

---

Storage: -80 °C

---

Expiry Date: 12 months

## Publications

---

Product cited in: Johnson, Drugan, Miller, Evans: "38" in: , Vol. 1363, Issue Nucleic acids research, pp. 28-39, (1991)